Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML0131

Sigma-Aldrich

ABT-751 hydrochloride

≥98% (HPLC)

Synonym(s):

N-[2-[(4-Hydroxyphenyl)amino]-3-pyridyl]-4-methoxybenzenesulfonamide hydrochloride

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C18H17N3O4S · HCl
CAS Number:
141450-48-8
Molecular Weight:
407.87
MDL number:
MFCD19440802
UNSPSC Code:
12352200
PubChem Substance ID:
329825181
NACRES:
NA.25

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

pink to purple

solubility

DMSO: ≥15 mg/mL

originator

Abbott

storage temp.

2-8°C

SMILES string

Cl.COc1ccc(cc1)S(=O)(=O)Nc2cccnc2Nc3ccc(O)cc3

InChI

1S/C18H17N3O4S.ClH/c1-25-15-8-10-16(11-9-15)26(23,24)21-17-3-2-12-19-18(17)20-13-4-6-14(22)7-5-13;/h2-12,21-22H,1H3,(H,19,20);1H

InChI key

KWQWWUXRGIIBAS-UHFFFAOYSA-N

Biochem/physiol Actions

ABT-751 is an orally bioavailable vascular disrupting agent (VDA) with a broad spectrum of antitumor activity. It binds to the colchicine binding site on β-tubulin and inhibits polymerization of microtubules.
ABT-751, a sulfonamide antimitotic agent, is under clinical trials to treat patients with various malignancies including refractory hematologic malignancies, non-small cell lung cancer (NSCLC), and colon cancer.

Features and Benefits

This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302,H315,H319,H335

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Timothy J Jorgensen et al.
Cancer chemotherapy and pharmacology, 59(6), 725-732 (2006-09-13)
ABT-751 is an orally active antimitotic agent that is currently in Phase II clinical trials. This agent binds to the colchicine site on ss-tubulin and inhibits polymerization of microtubules. This disruption of microtubule dynamics leads to a block in the
Tian Ma et al.
Chemotherapy, 58(4), 321-329 (2012-11-14)
ABT-751 is a novel antimitotic agent that exerted cytotoxic effects in preclinical studies. Carboplatin has efficacy in treating advanced non-small cell lung cancer (NSCLC) in combination with other drugs. Lung cancer cell lines were treated with ABT-751 and/or carboplatin to
Karen W L Yee et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 11(18), 6615-6624 (2005-09-17)
ABT-751 is an oral antimitotic agent that binds to the colchicine site on beta-tubulin. A phase 1 study was conducted to determine the maximum tolerated dose and toxicities of ABT-751 in patients with advanced myelodysplastic syndrome and relapsed or refractory

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service